Seeing through VEGF: Innate and adaptive immunity in pathological angiogenesis in the eye

Abdoulaye Sene; David Chin-Yee; Rajendra S. Apte

doi:10.1016/j.molmed.2014.10.005

Seeing through VEGF: Innate and adaptive immunity in pathological angiogenesis in the eye

Abdoulaye Sene, David Chin-Yee, Rajendra S. Apte

Research output: Contribution to journal › Review article › peer-review

116 Scopus citations

Abstract

The central role of vascular endothelial growth factor (VEGF) signaling in regulating normal vascular development and pathological angiogenesis has been documented in multiple studies. Ocular anti-VEGF therapy is highly effective for treating a subset of patients with blinding eye disorders such as diabetic retinopathy and neovascular age-related macular degeneration (AMD). However, chronic VEGF suppression can lead to adverse effects associated with poor visual outcomes due to the loss of prosurvival and neurotrophic capacities of VEGF. In this review, we discuss emerging evidence for immune-related mechanisms that regulate ocular angiogenesis in a VEGF-independent manner. These novel molecular and cellular pathways may provide potential therapeutic avenues for a multitarget strategy, preserving the neuroprotective functions of VEGF in those patients whose disease is unresponsive to VEGF neutralization.

Original language	English
Pages (from-to)	43-51
Number of pages	9
Journal	Trends in Molecular Medicine
Volume	21
Issue number	1
DOIs	https://doi.org/10.1016/j.molmed.2014.10.005
State	Published - 2015

Keywords

Age-related macular degeneration (AMD)
Angiogenesis
Diabetic retinopathy
Immune regulation
Neovascularization
Vascular endothelial growth factor (VEGF)

Access to Document

10.1016/j.molmed.2014.10.005

Cite this

@article{bbdf78377a8141d8845ddab87ea8284a,

title = "Seeing through VEGF: Innate and adaptive immunity in pathological angiogenesis in the eye",

abstract = "The central role of vascular endothelial growth factor (VEGF) signaling in regulating normal vascular development and pathological angiogenesis has been documented in multiple studies. Ocular anti-VEGF therapy is highly effective for treating a subset of patients with blinding eye disorders such as diabetic retinopathy and neovascular age-related macular degeneration (AMD). However, chronic VEGF suppression can lead to adverse effects associated with poor visual outcomes due to the loss of prosurvival and neurotrophic capacities of VEGF. In this review, we discuss emerging evidence for immune-related mechanisms that regulate ocular angiogenesis in a VEGF-independent manner. These novel molecular and cellular pathways may provide potential therapeutic avenues for a multitarget strategy, preserving the neuroprotective functions of VEGF in those patients whose disease is unresponsive to VEGF neutralization.",

keywords = "Age-related macular degeneration (AMD), Angiogenesis, Diabetic retinopathy, Immune regulation, Neovascularization, Vascular endothelial growth factor (VEGF)",

author = "Abdoulaye Sene and David Chin-Yee and Apte, {Rajendra S.}",

note = "Funding Information: This work was supported by a National Institutes of Health (NIH) grant R01EY019287; NIH Vision Core grant P30EY02687; the Carl Marshall Reeves and Mildred Almen Reeves Foundation Inc. Award; the Research to Prevent Blindness Inc. Career Development Award and Physician Scientist Award to R.S.A.; the American Federation for Aging Research; the Lacy Foundation Research Award; and the Thome Foundation. Publisher Copyright: {\textcopyright} 2014 Elsevier Ltd.",

year = "2015",

doi = "10.1016/j.molmed.2014.10.005",

language = "English",

volume = "21",

pages = "43--51",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

number = "1",

}

TY - JOUR

T1 - Seeing through VEGF

T2 - Innate and adaptive immunity in pathological angiogenesis in the eye

AU - Sene, Abdoulaye

AU - Chin-Yee, David

AU - Apte, Rajendra S.

N1 - Funding Information: This work was supported by a National Institutes of Health (NIH) grant R01EY019287; NIH Vision Core grant P30EY02687; the Carl Marshall Reeves and Mildred Almen Reeves Foundation Inc. Award; the Research to Prevent Blindness Inc. Career Development Award and Physician Scientist Award to R.S.A.; the American Federation for Aging Research; the Lacy Foundation Research Award; and the Thome Foundation. Publisher Copyright: © 2014 Elsevier Ltd.

PY - 2015

Y1 - 2015

N2 - The central role of vascular endothelial growth factor (VEGF) signaling in regulating normal vascular development and pathological angiogenesis has been documented in multiple studies. Ocular anti-VEGF therapy is highly effective for treating a subset of patients with blinding eye disorders such as diabetic retinopathy and neovascular age-related macular degeneration (AMD). However, chronic VEGF suppression can lead to adverse effects associated with poor visual outcomes due to the loss of prosurvival and neurotrophic capacities of VEGF. In this review, we discuss emerging evidence for immune-related mechanisms that regulate ocular angiogenesis in a VEGF-independent manner. These novel molecular and cellular pathways may provide potential therapeutic avenues for a multitarget strategy, preserving the neuroprotective functions of VEGF in those patients whose disease is unresponsive to VEGF neutralization.

AB - The central role of vascular endothelial growth factor (VEGF) signaling in regulating normal vascular development and pathological angiogenesis has been documented in multiple studies. Ocular anti-VEGF therapy is highly effective for treating a subset of patients with blinding eye disorders such as diabetic retinopathy and neovascular age-related macular degeneration (AMD). However, chronic VEGF suppression can lead to adverse effects associated with poor visual outcomes due to the loss of prosurvival and neurotrophic capacities of VEGF. In this review, we discuss emerging evidence for immune-related mechanisms that regulate ocular angiogenesis in a VEGF-independent manner. These novel molecular and cellular pathways may provide potential therapeutic avenues for a multitarget strategy, preserving the neuroprotective functions of VEGF in those patients whose disease is unresponsive to VEGF neutralization.

KW - Age-related macular degeneration (AMD)

KW - Angiogenesis

KW - Diabetic retinopathy

KW - Immune regulation

KW - Neovascularization

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=84927640278&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2014.10.005

DO - 10.1016/j.molmed.2014.10.005

M3 - Review article

C2 - 25457617

AN - SCOPUS:84927640278

SN - 1471-4914

VL - 21

SP - 43

EP - 51

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 1

ER -

Seeing through VEGF: Innate and adaptive immunity in pathological angiogenesis in the eye

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this